Navigation Links
Protein Sciences Expands License Agreement with UMN Pharma
Date:11/9/2010

MERIDEN, Conn., Nov. 9, 2010 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced that it has expanded its 2006 agreement with UMN Pharma, Inc. (UMN), to which it licensed exclusive rights to commercialize FluBlok® and PanBlok® (together "PSC's influenza vaccines") in the Japan market. The amendment allows UMN to enter into collaboration agreements with Astellas Pharma Inc. (Astellas) and IHI Corporation (IHI).  Astellas' role will be to support further development, licensure and marketing of PSC's influenza vaccines for the Japan market.  PSC received a portion of the up-front payment paid by Astellas and will be entitled to receive a portion of the development and sales milestones and double-digit royalties on sales.  UMN will retain manufacturing rights and has partnered with IHI to establish a commercial manufacturing facility in Japan.

PSC and UMN have further amended their license agreement to expand the territories for which UMN holds exclusive rights to commercialize PSC's influenza vaccines to include China, Hong Kong, Korea, Singapore and Taiwan.  PSC has received a significant up-front payment and will be entitled to milestones upon licensure and high single-digit royalties on sales in each country.  In the event UMN sublicenses such rights, PSC will be entitled to payments similar to those under UMN's agreement with Astellas.

Daniel Adams, Executive Chairman, said, "We look forward to working with UMN and Astellas, which we view as an ideal development and marketing partner for UMN, to secure licensure and commercialize our influenza vaccines in Japan.  We also believe that UMN is well suited to bringing the benefits of FluBlok and PanBlok to the additional countries."  He added, "These agreements together with other recent developments, including our contract with BARDA, are key to growing our Company."

About PSC

PSC is a privately held biopharmaceutical company based in Meriden, Connecticut whose mission is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses its platform production system to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. PSC's platform technology is covered by broad patents that include its proprietary expresSF+® cell insect line that is uses to make all of its and its GeneXpress® customers' products.

PSC's lead product is FluBlok, a seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutinin (HA) proteins.  FluBlok is manufactured using cell culture instead of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics, and is low in endotoxins.  PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that was accepted in June 2008 and received "Fast Track" designation in July 2008.  PSC anticipates that FluBlok may receive FDA approval within a few months.  In 2009 the Company was awarded a $34.5 million contract by the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services, to further develop a recombinant technology for the production of recombinant influenza vaccines for pandemic preparedness. This contract could be extended up to a total of five years with a total value of approximately $147 million.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
2. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
3. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
4. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
5. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
8. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
9. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):